ABSTRACT
BACKGROUND: Glioblastoma Multiforme (GBM) is one of the most aggressive and fatal brain cancers. The study of metabolites could be crucial for understanding GBM's biology and reveal new treatment strategies. METHODS: The GWAS data for GBM were sourced from the FinnGen database. A total of 1400 plasma metabolites were collected from the GWAS Catalog dataset. The cerebrospinal fluid (CSF) metabolites data were collected from subsets of participants in the WADRC and WRAP studies. We utilized the inverse variance weighting (IVW) method as the primary tool to explore the causal relationship between metabolites in plasma and CSF and glioblastoma, ensuring the exclusion of instances with horizontal pleiotropy. Additionally, four supplementary analytical methods were applied to reinforce our findings. Aberrant results were identified and omitted based on the outcomes of the leave-one-out sensitivity analysis. Conclusively, a reverse Mendelian Randomization analysis was also conducted to further substantiate our results. RESULTS: The study identified 69 plasma metabolites associated with GBM. Of these, 40 metabolites demonstrated a significant positive causal relationship with GBM, while 29 exhibited a significant negative causal association. Notably, Trimethylamine N-oxide (TMAO) levels in plasma, not CSF, were found to be a significant exposure factor for GBM (OR = 3.1627, 95% CI = (1.6347, 6.1189), P = 0.0006). The study did not find a reverse causal relationship between GBM and plasma TMAO levels. CONCLUSIONS: This research has identified 69 plasma metabolites potentially associated with the incidence of GBM, among which TMAO stands out as a promising candidate for an early detectable biomarker for GBM.
Subject(s)
Brain Neoplasms , Genome-Wide Association Study , Glioblastoma , Mendelian Randomization Analysis , Humans , Glioblastoma/cerebrospinal fluid , Glioblastoma/blood , Glioblastoma/genetics , Brain Neoplasms/cerebrospinal fluid , Brain Neoplasms/genetics , Brain Neoplasms/blood , Biomarkers, Tumor/cerebrospinal fluid , Biomarkers, Tumor/blood , Biomarkers, Tumor/genetics , Methylamines/blood , Methylamines/cerebrospinal fluid , Female , MaleABSTRACT
Patients diagnosed with glioblastoma (GBM) have the most aggressive tumor progression and lethal recurrence. Research on the immune microenvironment landscape of tumor and cerebrospinal fluid (CSF) is limited. At the single-cell level, we aim to reveal the recurrent immune microenvironment of GBM and the potential CSF biomarkers and compare tumor locations. We collected four clinical samples from two patients: malignant samples from one recurrent GBM patient and non-malignant samples from a patient with brain tumor. We performed single-cell RNA sequencing (scRNA-seq) to reveal the immune landscape of recurrent GBM and CSF. T cells were enriched in the malignant tumors, while Treg cells were predominately found in malignant CSF, which indicated an inhibitory microenvironment in recurrent GBM. Moreover, macrophages and neutrophils were significantly enriched in malignant CSF. This indicates that they an important role in GBM progression. S100A9, extensively expressed in malignant CSF, is a promising biomarker for GBM diagnosis and recurrence. Our study reveals GBM's recurrent immune microenvironment after chemoradiotherapy and compares malignant and non-malignant CSF samples. We provide novel targets and confirm the promise of liquid CSF biopsy for patients with GBM.
Subject(s)
Brain Neoplasms , Glioblastoma , Neoplasm Recurrence, Local , Single-Cell Analysis , T-Lymphocytes, Regulatory , Tumor Microenvironment , Humans , Glioblastoma/immunology , Glioblastoma/pathology , Glioblastoma/cerebrospinal fluid , Tumor Microenvironment/immunology , T-Lymphocytes, Regulatory/immunology , T-Lymphocytes, Regulatory/metabolism , Neoplasm Recurrence, Local/immunology , Single-Cell Analysis/methods , Brain Neoplasms/immunology , Brain Neoplasms/pathology , Brain Neoplasms/cerebrospinal fluid , Brain Neoplasms/genetics , Biomarkers, Tumor/cerebrospinal fluid , Biomarkers, Tumor/metabolism , MaleABSTRACT
Os autores descrevem um raro caso de hipertensäo intracraniana conseqüente a glioblastoma multiforme situado na medula cervical de uma paciente jovem. Analisam a fisiopatologia de hipertensäo intracraniana em tumores medulares e a raridade desse tipo de tumor nessa localizaçäo, assim como seus aspectos clínico-patológicos